Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03689010 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,116
- Enrollment target
NCT03689010: Completed Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT03689010 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 1,116 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1760% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03689010, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,116 participants
- Enrollment target
Study Summary
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
Primary Outcome
Percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts
Interventions
- DRUG Azelaic acid foam 15%
- DRUG Finacea® (Azelaic acid Foam) 15%
- DRUG Vehicle of the test product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,116 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2018-09-28 |
| Phase | Phase 1 |
What the finished NCT03689010 record still lists
NCT03689010 is an interventional study that assigns participants to a tested intervention. Its 1,116 participants enrollment target places it among the larger protocols in the corpus, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1760% higher).
The record links to 0 conditions, and to 3 interventions - of which Azelaic acid foam 15% is the first listed.
NCT03689010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03689010 about?
NCT03689010 is a clinical study titled "To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea". To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
What is the current status of trial NCT03689010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,116 participants. The study started on 2017-12-12. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT03689010?
The interventions under investigation include: Azelaic acid foam 15% (DRUG), Finacea® (Azelaic acid Foam) 15% (DRUG), Vehicle of the test product (DRUG).
Who is sponsoring clinical trial NCT03689010?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03689010's enrollment target sits among peer trials
1,116 6th of 2000 higher than 1,995 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI